IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.

CD39 is an extracellular enzyme that is expressed in the tumor microenvironment, on both tumor infiltrating cells and stromal cells in several cancer types. CD39 inhibits the immune system by degrading adenosine tripohsphate (ATP) into adenosine monophosphate (AMP), that is then further degraded into adenosine by CD73. By promoting the accumulation of immune-stimulating ATP, and preventing the production of immune-suppressive adenosine, the blockade of CD39 may stimulate anti-tumor activity.

Mechanism of action of IPH5201

Mechanism of action of IPH5201


AstraZeneca conducted a Phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab.

IPH5201 is being investigated in a Phase 2 clinical trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC). 

The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. 

Innate is responsible for conducting the study and shares study costs with AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca supplies clinical trial drugs.

In October 2018, Innate Pharma and AstraZeneca entered into a development collaboration and option agreement for further co-development and co-commercialization for IPH5201.

Learn more about Innate’s partnership with AstraZeneca

Publications, posters and presentations